Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A community approach to the cancer-variant-interpretation bottleneck

As guidelines, therapies and literature on cancer variants expand, the lack of consensus variant interpretations impedes clinical applications. CIViC is a public-domain, crowd-sourced and adaptable knowledgebase of evidence for the clinical interpretation of variants in cancer, designed to reduce barriers to knowledge sharing and alleviate the variant-interpretation bottleneck.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Evolution of CIViC user engagement.
Fig. 2: CIViC data model updates and curation activity.


  1. Griffith, M. et al. Nat. Genet. 49, 170–174 (2017).

    CAS  Article  Google Scholar 

  2. Danos, A. M. et al. Genome Med. 11, 76 (2019).

    Article  Google Scholar 

  3. Pleasance, E. et al. Nat. Cancer 1, 452–468 (2020).

  4. Madhavan, S. et al. Pac. Symp. Biocomput. 23, 247–258 (2018).

    PubMed  PubMed Central  Google Scholar 

  5. Wagner, A. H. et al. Nat. Genet. 52, 448–457 (2020).

    CAS  Article  Google Scholar 

  6. Zhou, X. et al. Nat. Genet. 48, 4–6 (2016).

    CAS  Article  Google Scholar 

  7. Pratt, D. et al. Cancer Res. 77, e58–e61 (2017).

    CAS  Article  Google Scholar 

  8. Pagel, K. A. et al. JCO Clin. Cancer Inform. 4, 310–317 (2020).

  9. Pawliczek, P. et al. Hum. Mutat. 39, 1690–1701 (2018).

    Article  Google Scholar 

  10. Nielsen, S. M. et al. J. Clin. Oncol. 34, 2172–2181 (2016).

    CAS  Article  Google Scholar 

  11. Li, M. M. et al. J. Mol. Diagn. 19, 4–23 (2017).

    CAS  Article  Google Scholar 

  12. Danos, A. M. et al. Hum. Mutat. 39, 1721–1732 (2018).

    Article  Google Scholar 

  13. Richards, S. et al. Genet. Med. 17, 405–424 (2015).

    Article  Google Scholar 

  14. Köhler, S. et al. Nucleic Acids Res. 49, D1207–D1217 (2021).

    Article  Google Scholar 

  15. Horak, P. et al. Genet. Med. 24, 986–998 (2022).

Download references

Author information

Authors and Affiliations


Corresponding authors

Correspondence to Kilannin Krysiak, Obi L. Griffith or Malachi Griffith.

Ethics declarations

Competing interests

E.K.B. is an owner, employee and member of Geneoscopy, and an inventor of the intellectual property owned by Geneoscopy. K.M.C. is a shareholder in Geneoscopy and has received honoraria from PACT Pharma and Tango Therapeutics. D.T.R. provides consulting for Alacris Theranostics and has received honoraria from Bayer, Eli Lilly and Bristol Myers Squibb.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Krysiak, K., Danos, A.M., Kiwala, S. et al. A community approach to the cancer-variant-interpretation bottleneck. Nat Cancer 3, 522–525 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer